The Office of Governor John Hickenlooper is using the Center for leadership and assistance in coordinating multi-payer activities, coordinating with provider recruitment and support, and managing multi-payer data aggregation for its SIM Implementation Grant.
This report examines naloxone programs in various stages of development in three states and summarizes Medicaid coverage policies in ten states.
The Center searched all 50 Medicaid agency websites, including provider manuals (pharmacy and medical), preferred drug lists, committee meeting minutes and agendas, and state statute or administrative rule websites, to identify states with policies for Harvoni® and Viekira PakTM.
With the FDA approval of sofosbuvir, clinicians and purchasers will need to decide whether to include sofosbuvir in their treatment protocols for HCV infection. This report evaluates the evidence about the effectiveness and harms of sofosbuvir treatment for HCV, evaluates the AASLD guideline, and provides a compilation of the evidence to guide decisions on who and when to treat.
This report describes well-developed HTA programs from the US, Canada, Australia and select European countries. Individual HTA programs were identified on the availability of having documents in English and/or that were discussed in the International Journal of Technology Assessment in Health Care 2009 supplemental volumes (Suppl 1 and 2) on HTA programs.